Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes

IMPORTANCE: Measurable residual disease (MRD) is widely used as a therapy-stratification factor for acute myeloid leukemia (AML), but the association of dynamic MRD with postremission treatment (PRT) in patients with intermediate-risk AML (IR-AML) has not been well investigated. OBJECTIVE: To invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Sijian, Fan, Zhiping, Ma, Liping, Wang, Yu, Huang, Fen, Zhang, Qing, Huang, Jiafu, Wang, Shunqing, Xu, Na, Xuan, Li, Xiong, Mujun, Han, Lijie, Sun, Zhiqiang, Zhang, Hongyu, Liu, Hui, Yu, Guopan, Shi, Pengcheng, Xu, Jun, Wu, Meiqing, Guo, Ziwen, Xiong, Yiying, Duan, Chongyang, Sun, Jing, Liu, Qifa, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264648/
https://www.ncbi.nlm.nih.gov/pubmed/34232303
http://dx.doi.org/10.1001/jamanetworkopen.2021.15991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264648/
https://www.ncbi.nlm.nih.gov/pubmed/34232303
http://dx.doi.org/10.1001/jamanetworkopen.2021.15991

Ejemplares similares